Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Core Insights - Precision BioSciences, Inc. will report its financial results for the fourth quarter and fiscal year 2025 on March 12, 2026, along with a business update [1] - The company specializes in gene editing therapies using its proprietary ARCUS® platform, aimed at addressing high unmet medical needs [1] Company Overview - Precision BioSciences is a clinical stage gene editing company based in Durham, North Carolina, focusing on in vivo gene editing therapies [1] - The ARCUS® platform is characterized by its unique cutting mechanism, smaller size, and simpler structure, which are designed to achieve more defined therapeutic outcomes [1] - The company's pipeline includes clinical stage candidates targeting genetic and infectious diseases where existing treatments are inadequate [1] Recent Developments - The FDA has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD) [1] - Precision BioSciences received $7.5 million from TG Therapeutics for achieving a clinical milestone related to the azercabtagene zapreleucel (azer-cel) in multiple sclerosis [1] - New preclinical study data supporting the safety and long-term efficacy of PBGENE-DMD will be presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference [1]